The Indian Council of Medical Research (ICMR) has said that India’s indigenous vaccine against coronavirus -- Covaxin, has attracted global attention. ICMR in a tweet said, "India's indigenous vaccine against #COVID19 Covaxin-a product of ICMR-Bharat Biotech collaboration, achieves the remarkable feat. Data generated from within India underlines an impressive safety and immunogenicity profile of Covaxin and sparks Lancet's interest in publishing them."
The ICMR said, "Encouraging Phase I and Phase II COVAXIN trial results have paved the path for Phase III Clinical Trial in India, which is currently ongoing at 22 sites."
New Delhi’s All India Institute of Medical Sciences (AIIMS) based on Thursday invited volunteers to take part in Phase three clinical trial of the indigenously developed coronavirus vaccine candidate ''Covaxin'' for which it is one of the sites.
Also Read: Punjab to conduct dry run of Covid-19 vaccine on Dec 28 & 29, says Balbir Singh Sidhu
AIIMS in an advertisement said, "AIIMS, New Delhi is a site for COVAXIN Phase III clinical trial. This is a whole-virion inactivated vaccine co-sponsored by the Indian Council of Medical Research (ICMR) and Bharat Biotech.”
AIIMS Centre for Community Medicine, Dr Sanjay K Rai informed through the advertisement that Phase one and two trials (safety and immunogenicity) have already been completed.